Central Nervous System Biomarkers Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 5.61 Billion |
| Market Size (2029) | USD 8.12 Billion |
| CAGR (2024 - 2029) | 7.67 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Central Nervous System Biomarkers Market Analysis
The Global Central Nervous System Biomarkers Market size is estimated at USD 5.61 billion in 2024, and is expected to reach USD 8.12 billion by 2029, growing at a CAGR of 7.67% during the forecast period (2024-2029).
COVID-19 cases worldwide had a profound impact on the CNS biomarkers market. Based on the study "Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity," published in January 2021, various studies found frequent reporting of neurological symptoms in patients hospitalized due to COVID-19. Thus, the researchers examined cerebrospinal fluid (CSF) from patients with neurological manifestations of COVID-19 for biomarkers of the central nervous system (CNS) injury and other pathology in relation to neurological symptoms and disease severity. Therefore, future studies in larger samples are needed to explore and understand the genesis of neurological injury in COVID-19 patients.
A biomarker is used to measure the biological state, presence of diseases, and effects of treatments. The advancements in the fields of genomics and proteomics during the past decade have improved awareness regarding genetic regulatory pathways related to (central nervous system) CNS biomarkers. The proteomics technologies have advanced in various areas of drug discovery and development through a comparative assessment of normal and diseased tissues. Proteomics research has great potential in the discovery of relevant protein biomarkers in both diagnostics and therapies for the central nervous system. It plays a crucial role in earlier disease diagnosis, prognosis, and monitoring of the development of central nervous disease.
There is also an increasing number of pipeline studies for the development of biomarkers in various disease conditions, which is expected to boost the central nervous system biomarkers market growth. According to the study "Biomarkers in tumors of the central nervous system" published in 2019, specific diagnostic, prognostic, and predictive biomarkers were detected, and they continue to emerge. Hence, the knowledge of specific biomarkers is of great importance for individualized treatment and follow-up.
Therefore, advanced imaging systems are aiding the early diagnosis of various diseases while reducing the mortality rate. The development in related technologies, such as genomics, proteomics, and imaging system, is reflected in the evolution of newer biomarkers. Considering the complexity of the central nervous system (CNS), biomarkers are now expected to play a significant role in the identification of several neurodegenerative diseases at an early stage, provide enhanced diagnosis, and eventually better treatment.
However, the high cost of CNS biomarker testing and diagnostics and certain issues related to regulatory and reimbursement systems are found to be the hindering factors impacting the growth of the market.
Central Nervous System Biomarkers Market Trends
This section covers the major market trends shaping the Central Nervous System Biomarkers Market according to our research experts:
Personalized Medicine Segment Expected to Show Better Growth in the Forecast Period
Precision medicine, or personalized medicine, is found to be one of the most promising approaches to tackling various diseases. The major factors that are contributing to the growth of the market are the rising number of brain and other nervous system cancers. It has its rising application as a diagnostic tool, which helps in recognizing the precise biological markers. There is an increasing number of companies that are found focusing on developing breakthrough products for the treatment of neurological diseases.
The COVID-19 pandemic impacted the personalized medicine segment. Precision medicine (PM) aims to tailor treatment and interventions to unique individual or population-level traits. Therefore, personalized medicine is relevant for addressing COVID-19 illness. The San Antonio Partnership for Precision Therapeutics (SAPPT) also announced the funding of three projects that would accelerate treatments for COVID-19 using precision medicine principles.
Biomarker research in neurodegenerative disease is a rapidly advancing area in personalized medicine. The role of these markers is not only diagnostic, but they also have prognostic potential or role in the development of new treatments. Therefore, a large number of molecules have been evaluated and associated with different neurodegenerative disorders. Alzheimer's disease and Parkinson's disease are found to be the two most common neurodegenerative disorders.
This evolution within precision medicine has profoundly impacted the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change. Therefore, all these factors have helped in boosting the overall market.
North America Dominates the Central Nervous System Biomarkers Market
The growing burden of chronic diseases, rise in the development of proteomics, genomics, and imaging systems, and increasing adoption of personalized medicines and therapy are expected to drive the central nervous system (CNS) biomarkers market in the United States.
The increasing neurological symptoms have been frequently reported in hospitalized patients with COVID-19, and biomarkers of central nervous system (CNS) injury are reported to be increased in plasma but not extensively studied in cerebrospinal fluid (CSF). Therefore with the rising COVID-19 cases, there is increasing evidence of central nervous system (CNS) damage in COVID-19 patients by using serological biomarkers.
According to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the United States. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.
The molecular biomarkers are used for various purposes, including CNS disease diagnosis, prognosis, prediction, and assessment of treatment response and safety. Almost every pharmaceutical company is formulating a molecular biomarker program, either alone or through partnerships. More molecular biomarkers are expected to be identified and validated in drug development.
In 2019, MC10 Inc. announced the collaboration with the University of Rochester for the development of novel digital biomarkers for central nervous system diseases. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.
Central Nervous System Biomarkers Industry Overview
The global players in the central nervous system biomarkers market include Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd, Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, Merck KGaA, and Thermo Fisher Scientific Inc. The players strategically invest in the research and development for innovative and technological advancements and focus on partnerships with domestic players to expand their outreach.
Central Nervous System Biomarkers Market Leaders
-
G-Biosciences
-
Merck KGaA
-
Thermo Fisher Scientific Inc.
-
Bio-Rad Laboratories, Inc.
-
Biomeriux (Banyan Biomarkers Inc.)
*Disclaimer: Major Players sorted in no particular order
Central Nervous System Biomarkers Market News
- In November 2021, Eisai Co. Ltd and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for Alzheimer's disease.
- In October 2021, Diadem announced the publication of clinical data showing its AlzoSure biomarker test is able to predict the progression of Alzheimer's disease years before symptoms are displayed.
Central Nervous System Biomarkers Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in the Development in Proteomics, Genomics, and Imaging System
- 4.2.2 Rising Investments from Government and Private Players
- 4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers
-
4.3 Market Restraints
- 4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics
- 4.3.2 Reimbursement and Regulatory Issues
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Type of CNS Biomarkers
- 5.1.1 Safety Biomarkers
- 5.1.2 Efficacy Biomarkers
- 5.1.3 Validation Biomarkers
- 5.1.4 Other Types of CNS Biomarkers
-
5.2 By Application
- 5.2.1 Drug Discovery and Development
- 5.2.2 Personalized Medicine
- 5.2.3 Other Applications
-
5.3 By End User
- 5.3.1 Diagnostic Labs
- 5.3.2 Clinics/Hospitals
- 5.3.3 Research Centers
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Acumen Pharmaceuticals Inc.
- 6.1.2 Alseres Pharmaceuticals Inc.
- 6.1.3 Avacta Life Sciences Limited
- 6.1.4 Biomeriux (Banyan Biomarkers Inc.)
- 6.1.5 Bio-Rad Laboratories Inc.
- 6.1.6 G-Biosciences
- 6.1.7 Merck KGaA
- 6.1.8 Thermo Fisher Scientific Inc.
- 6.1.9 Eli Lilly and Company (Avid radiopharmaceuticals Inc.)
- 6.1.10 Proteome Sciences PLC (Service)
- 6.1.11 Enzo Biochem Inc. (Product Found)
- 6.1.12 H.U. Group Holdings (Fujirebio)
- 6.1.13 Acro Biosystems
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCentral Nervous System Biomarkers Industry Segmentation
As per the scope of the report, central nervous system (CNS) biomarkers are used clinically to screen for, diagnose, or monitor the activity of CNS-related diseases to guide molecularly targeted therapy or assess therapeutic response. Biomarkers help understand the development of chronic diseases and their relationship with environmental chemicals and identify subjects who are at high risk of developing diseases. The central nervous system biomarkers market is segmented by type of CNS biomarkers (safety biomarker, efficacy biomarker, validation biomarker, and other types of CNS biomarkers), application (drug discovery and development, personalized medicine, and other applications), end user (diagnostic labs, clinics/hospitals, and research centers), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Type of CNS Biomarkers | Safety Biomarkers | |
| Efficacy Biomarkers | ||
| Validation Biomarkers | ||
| Other Types of CNS Biomarkers | ||
| By Application | Drug Discovery and Development | |
| Personalized Medicine | ||
| Other Applications | ||
| By End User | Diagnostic Labs | |
| Clinics/Hospitals | ||
| Research Centers | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Central Nervous System Biomarkers Market Research FAQs
How big is the Global Central Nervous System Biomarkers Market?
The Global Central Nervous System Biomarkers Market size is expected to reach USD 5.61 billion in 2024 and grow at a CAGR of 7.67% to reach USD 8.12 billion by 2029.
What is the current Global Central Nervous System Biomarkers Market size?
In 2024, the Global Central Nervous System Biomarkers Market size is expected to reach USD 5.61 billion.
Who are the key players in Global Central Nervous System Biomarkers Market?
G-Biosciences, Merck KGaA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc. and Biomeriux (Banyan Biomarkers Inc.) are the major companies operating in the Global Central Nervous System Biomarkers Market.
Which is the fastest growing region in Global Central Nervous System Biomarkers Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Central Nervous System Biomarkers Market?
In 2024, the North America accounts for the largest market share in Global Central Nervous System Biomarkers Market.
What years does this Global Central Nervous System Biomarkers Market cover, and what was the market size in 2023?
In 2023, the Global Central Nervous System Biomarkers Market size was estimated at USD 5.21 billion. The report covers the Global Central Nervous System Biomarkers Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Central Nervous System Biomarkers Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
CNS Biomarkers Industry Report
Statistics for the 2024 CNS Biomarkers market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. CNS Biomarkers analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
